TheMysTrader的个人主页 - 老虎社区

TheMysTrader

TheMysTrader

暂无个人介绍

IP属地：未知

11关注

4粉丝

0主题

0勋章

2021-11-29

Will tesla 🚀 to a whole new level?

Tesla stock rallied nearly 3% in premarket trading

2021-11-27

$Sea Ltd(SE)$ awww where's the last hr sales

2021-11-05

Buy the slid wheee

抱歉，原内容已删除

2021-11-05

Will Pfizer for once pfi(fly) up to the moon? [财迷]

Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%

2021-11-05

Omg that's good news!

Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%

2021-10-21

Will $Tesla Motors(TSLA)$hit 900 alike earlier part of the year?

2021-06-24

Wow

抱歉，原内容已删除

2021-06-24

Bbtea ❤️

抱歉，原内容已删除

2021-06-17

Wow[得意]

Facebook's Hardware Business Is Creeping Into Apple's Backyard

2021-06-17

Interesting

Facebook's Hardware Business Is Creeping Into Apple's Backyard

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3574940915326235","uuid":"3574940915326235","gmtCreate":1611848582544,"gmtModify":1638180009533,"name":"TheMysTrader","pinyin":"themystrader","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":11,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.11","exceedPercentage":"60.41%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":600554198,"gmtCreate":1638178262115,"gmtModify":1638178262281,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Will tesla 🚀 to a whole new level?","listText":"Will tesla 🚀 to a whole new level?","text":"Will tesla 🚀 to a whole new level?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600554198","repostId":"1180553445","repostType":4,"repost":{"id":"1180553445","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638177356,"share":"https://www.laohu8.com/m/news/1180553445?lang=&edition=full","pubTime":"2021-11-29 17:15","market":"us","language":"en","title":"Tesla stock rallied nearly 3% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1180553445","media":"Tiger Newspress","summary":"Tesla stock rallied nearly 3% in premarket trading as it to start production in Germany in December,","content":"<p>Tesla stock rallied nearly&nbsp;3% in premarket trading&nbsp;as&nbsp;it to start production in Germany in December,according to&nbsp;Automobilwoche.</p>\n<p><img src=\"https://static.tigerbbs.com/c924dd7ad062e13f25605d196e86462b\" tg-width=\"853\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p>\n<p>Tesla Inc. will launch its overdue German production operations in December, Automobilwoche reported, estimating as many as 30,000 vehicles will be manufactured there in the first half of 2022.</p>\n<p>Production was to have begun in July but was delayed because the company hadn’t received environmental clearance. Local regulators are expected to grant the necessary permits within days, the magazine said, without reporting where it received its information.</p>\n<p>Five units of Model Y have already been completed at the Gigafactory near Berlin, though not on the production line. In January, serial production will start with 1,000 cars per week and gradually increase, according to Automobilwoche.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla stock rallied nearly 3% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla stock rallied nearly 3% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-29 17:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla stock rallied nearly&nbsp;3% in premarket trading&nbsp;as&nbsp;it to start production in Germany in December,according to&nbsp;Automobilwoche.</p>\n<p><img src=\"https://static.tigerbbs.com/c924dd7ad062e13f25605d196e86462b\" tg-width=\"853\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p>\n<p>Tesla Inc. will launch its overdue German production operations in December, Automobilwoche reported, estimating as many as 30,000 vehicles will be manufactured there in the first half of 2022.</p>\n<p>Production was to have begun in July but was delayed because the company hadn’t received environmental clearance. Local regulators are expected to grant the necessary permits within days, the magazine said, without reporting where it received its information.</p>\n<p>Five units of Model Y have already been completed at the Gigafactory near Berlin, though not on the production line. In January, serial production will start with 1,000 cars per week and gradually increase, according to Automobilwoche.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180553445","content_text":"Tesla stock rallied nearly 3% in premarket trading as it to start production in Germany in December,according to Automobilwoche.\n\nTesla Inc. will launch its overdue German production operations in December, Automobilwoche reported, estimating as many as 30,000 vehicles will be manufactured there in the first half of 2022.\nProduction was to have begun in July but was delayed because the company hadn’t received environmental clearance. Local regulators are expected to grant the necessary permits within days, the magazine said, without reporting where it received its information.\nFive units of Model Y have already been completed at the Gigafactory near Berlin, though not on the production line. In January, serial production will start with 1,000 cars per week and gradually increase, according to Automobilwoche.","news_type":1},"isVote":1,"tweetType":1,"viewCount":720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877561413,"gmtCreate":1637944348124,"gmtModify":1637944348124,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>&nbsp;awww where's the last hr sales","listText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>&nbsp;awww where's the last hr sales","text":"$Sea Ltd(SE)$ awww where's the last hr sales","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877561413","isVote":1,"tweetType":1,"viewCount":955,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846711921,"gmtCreate":1636113379725,"gmtModify":1636113503105,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Buy the slid wheee","listText":"Buy the slid wheee","text":"Buy the slid wheee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846711921","repostId":"1136485403","repostType":2,"isVote":1,"tweetType":1,"viewCount":745,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846797989,"gmtCreate":1636112138356,"gmtModify":1636112280599,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Will Pfizer for once pfi(fly) up to the moon?&nbsp;[财迷]&nbsp;","listText":"Will Pfizer for once pfi(fly) up to the moon?&nbsp;[财迷]&nbsp;","text":"Will Pfizer for once pfi(fly) up to the moon? [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/846797989","repostId":"1168526565","repostType":2,"repost":{"id":"1168526565","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636109309,"share":"https://www.laohu8.com/m/news/1168526565?lang=&edition=full","pubTime":"2021-11-05 18:48","market":"us","language":"en","title":"Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168526565","media":"Tiger Newspress","summary":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug wa","content":"<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p>\n<p>The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p>\n<p>Full trial data is not yet available from either company.</p>\n<p>Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p>\n<p>The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p>\n<p>The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p>\n<p>It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p>\n<p>Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p>\n<p>Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p>\n<p>\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p>\n<p>The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p>\n<p>\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p>\n<p>Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p>\n<p>Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p>\n<p>Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p>\n<p>Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p>\n<p>Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p>\n<p>Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-05 18:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p>\n<p>The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p>\n<p>Full trial data is not yet available from either company.</p>\n<p>Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p>\n<p>The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p>\n<p>The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p>\n<p>It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p>\n<p>Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p>\n<p>Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p>\n<p>\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p>\n<p>The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p>\n<p>\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p>\n<p>Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p>\n<p>Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p>\n<p>Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p>\n<p>Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p>\n<p>Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p>\n<p>Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168526565","content_text":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.\nThe results appear to surpass those seen with Merck & Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.\nFull trial data is not yet available from either company.\nPfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.\nThe combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.\nThe planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.\nIt found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.\nRates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.\nAntivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.\n\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.\nThe company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.\n\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.\nInfectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.\nPfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.\nMerck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.\nBritain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.\nPfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.\nIts shares rose over 9% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":942,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846798097,"gmtCreate":1636111622666,"gmtModify":1636111622737,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Omg that's good news!&nbsp;","listText":"Omg that's good news!&nbsp;","text":"Omg that's good news!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846798097","repostId":"1168526565","repostType":2,"repost":{"id":"1168526565","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636109309,"share":"https://www.laohu8.com/m/news/1168526565?lang=&edition=full","pubTime":"2021-11-05 18:48","market":"us","language":"en","title":"Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168526565","media":"Tiger Newspress","summary":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug wa","content":"<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p>\n<p>The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p>\n<p>Full trial data is not yet available from either company.</p>\n<p>Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p>\n<p>The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p>\n<p>The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p>\n<p>It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p>\n<p>Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p>\n<p>Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p>\n<p>\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p>\n<p>The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p>\n<p>\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p>\n<p>Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p>\n<p>Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p>\n<p>Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p>\n<p>Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p>\n<p>Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p>\n<p>Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-05 18:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p>\n<p>The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p>\n<p>Full trial data is not yet available from either company.</p>\n<p>Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p>\n<p>The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p>\n<p>The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p>\n<p>It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p>\n<p>Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p>\n<p>Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p>\n<p>\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p>\n<p>The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p>\n<p>\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p>\n<p>Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p>\n<p>Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p>\n<p>Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p>\n<p>Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p>\n<p>Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p>\n<p>Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168526565","content_text":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.\nThe results appear to surpass those seen with Merck & Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.\nFull trial data is not yet available from either company.\nPfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.\nThe combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.\nThe planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.\nIt found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.\nRates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.\nAntivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.\n\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.\nThe company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.\n\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.\nInfectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.\nPfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.\nMerck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.\nBritain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.\nPfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.\nIts shares rose over 9% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1049,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853937233,"gmtCreate":1634755270098,"gmtModify":1634755270227,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Will&nbsp;<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>hit 900 alike earlier part of the year?&nbsp;","listText":"Will&nbsp;<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>hit 900 alike earlier part of the year?&nbsp;","text":"Will $Tesla Motors(TSLA)$hit 900 alike earlier part of the year?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853937233","isVote":1,"tweetType":1,"viewCount":687,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":128865013,"gmtCreate":1624510533832,"gmtModify":1634005038213,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128865013","repostId":"1170004118","repostType":4,"isVote":1,"tweetType":1,"viewCount":129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128868955,"gmtCreate":1624510444177,"gmtModify":1634005040737,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Bbtea ❤️","listText":"Bbtea ❤️","text":"Bbtea ❤️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128868955","repostId":"1178700711","repostType":4,"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163327019,"gmtCreate":1623860210331,"gmtModify":1634026865490,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Wow[得意]&nbsp;","listText":"Wow[得意]&nbsp;","text":"Wow[得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163327019","repostId":"2143978737","repostType":4,"repost":{"id":"2143978737","pubTimestamp":1623857100,"share":"https://www.laohu8.com/m/news/2143978737?lang=&edition=full","pubTime":"2021-06-16 23:25","market":"us","language":"en","title":"Facebook's Hardware Business Is Creeping Into Apple's Backyard","url":"https://stock-news.laohu8.com/highlight/detail?id=2143978737","media":"Motley Fool","summary":"But Apple shouldn't lose any sleep over Facebook's smartwatch plans.","content":"<p><b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b> (NASDAQ:FB) could be developing a smartwatch with two cameras, according to The Verge. The camera on the front will likely be used for video calls, while the rear camera can be detached to capture photos and videos for Facebook's family of apps.</p>\n<p>Facebook is also reportedly in talks with companies to develop accessories for attaching the camera to backpacks and other objects. Previous rumors regarding the watch suggested it will sport health-tracking features, run on a stand-alone cellular connection, and use a custom version of the Android operating system. Could this long-rumored device help Facebook challenge <b>Apple</b> (NASDAQ:AAPL) in the smartwatch market?</p>\n<h2>Why is Facebook developing a smartwatch?</h2>\n<p>Facebook generated 97% of its revenue from ads last quarter. The remaining 3% came from its \"other\" businesses, which include its Oculus virtual reality (VR) headsets and Portal smart screens. It might initially seem odd for Facebook to add a smartwatch to that lineup, but it would actually complement its previous hardware strategies.</p>\n<p>Facebook's strongest hardware business is its lineup of Oculus VR headsets. It could ship at least three million Oculus Quest 2 headsets this year, according to SuperData. That would make the stand-alone VR headset, which doesn't require a PC or phone, the clear leader of its niche market.</p>\n<p>Looking beyond VR devices, Facebook is developing augmented reality (AR) glasses that will use similar controls as its Oculus headsets. It also acquired CTRL-Labs, which is developing a wristband that can use brain signals to control computers, in late 2019. In theory, CTRL-Labs' technology could eventually enable users to control VR and AR devices with \"mind-reading\" wristbands instead of controllers in the future.</p>\n<p>Meanwhile, Facebook's Portal devices haven't gained much momentum against <b>Amazon</b> (NASDAQ:AMZN) or <b>Alphabet</b>'s (NASDAQ:GOOGL) (NASDAQ:GOOG) Google in the smart screen market. That failure likely dashed Facebook's hopes of expanding its social networking platforms beyond PCs and phones and into connected homes.</p>\n<p>When you put all those pieces together, you'll realize Facebook's smartwatch could be used to enhance control of its VR and AR devices, or to expand its social networks into the Internet of Things (IoT) and perhaps succeed where the Portal failed. Facebook could also eventually upgrade its watches with CTRL-Labs' technologies and enable users to control other IoT devices with their minds.</p>\n<h2>But let's not get ahead of ourselves... yet</h2>\n<p>Facebook has reportedly spent about $1 billion on the development of its smartwatch over the past few years, but it only initially plans to ship volumes in the low six figures.</p>\n<p>That would make Facebook a tiny smartwatch maker compared to <b>Apple</b> (NASDAQ:AAPL), which grew its Apple Watch shipments 19% to 33.9 million in 2020, according to Counterpoint Research. Apple ended the year with a whopping 40% share of the global smartwatch market.</p>\n<p>Facebook likely realizes its smartwatch will face the same three problems that plagued the Portal: a deep distrust of Facebook's brand, privacy concerns, and its late arrival into a saturated market. Google also encountered similar criticisms after its recent takeover of Fitbit.</p>\n<p>Facebook reportedly plans to launch its smartwatch next summer for about $400. But a lot could happen within the next year, and new smartwatches -- including a new version of the Apple Watch -- could easily steal Facebook's thunder. A smartwatch with two cameras could also be considered complicated and redundant, especially when smartphones and action cameras serve the same purposes.</p>\n<h2>The key takeaways</h2>\n<p>The global smartwatch market could still grow from $59 billion this year to nearly $100 billion in 2025, according to Research and Markets. That's great news for Apple, but it also suggests the market might still be big enough for newcomers like Facebook to gain a foothold.</p>\n<p>But investors should take all these rumors with a grain of salt until Facebook actually makes an official announcement. Even if Facebook's smartwatch fares better than the Portal, it probably won't generate a meaningful percentage of its revenue or reduce its overall dependence on ads.</p>\n<p>Instead, it should be considered a potential expansion of its ecosystem beyond PCs and phones, which might just complement its ongoing push into the virtual and augmented reality markets.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Facebook's Hardware Business Is Creeping Into Apple's Backyard</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFacebook's Hardware Business Is Creeping Into Apple's Backyard\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 23:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/16/facebooks-hardware-business-is-creeping-into-apple/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Facebook (NASDAQ:FB) could be developing a smartwatch with two cameras, according to The Verge. The camera on the front will likely be used for video calls, while the rear camera can be detached to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/16/facebooks-hardware-business-is-creeping-into-apple/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09086":"华夏纳指-U","AAPL":"苹果","03086":"华夏纳指"},"source_url":"https://www.fool.com/investing/2021/06/16/facebooks-hardware-business-is-creeping-into-apple/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143978737","content_text":"Facebook (NASDAQ:FB) could be developing a smartwatch with two cameras, according to The Verge. The camera on the front will likely be used for video calls, while the rear camera can be detached to capture photos and videos for Facebook's family of apps.\nFacebook is also reportedly in talks with companies to develop accessories for attaching the camera to backpacks and other objects. Previous rumors regarding the watch suggested it will sport health-tracking features, run on a stand-alone cellular connection, and use a custom version of the Android operating system. Could this long-rumored device help Facebook challenge Apple (NASDAQ:AAPL) in the smartwatch market?\nWhy is Facebook developing a smartwatch?\nFacebook generated 97% of its revenue from ads last quarter. The remaining 3% came from its \"other\" businesses, which include its Oculus virtual reality (VR) headsets and Portal smart screens. It might initially seem odd for Facebook to add a smartwatch to that lineup, but it would actually complement its previous hardware strategies.\nFacebook's strongest hardware business is its lineup of Oculus VR headsets. It could ship at least three million Oculus Quest 2 headsets this year, according to SuperData. That would make the stand-alone VR headset, which doesn't require a PC or phone, the clear leader of its niche market.\nLooking beyond VR devices, Facebook is developing augmented reality (AR) glasses that will use similar controls as its Oculus headsets. It also acquired CTRL-Labs, which is developing a wristband that can use brain signals to control computers, in late 2019. In theory, CTRL-Labs' technology could eventually enable users to control VR and AR devices with \"mind-reading\" wristbands instead of controllers in the future.\nMeanwhile, Facebook's Portal devices haven't gained much momentum against Amazon (NASDAQ:AMZN) or Alphabet's (NASDAQ:GOOGL) (NASDAQ:GOOG) Google in the smart screen market. That failure likely dashed Facebook's hopes of expanding its social networking platforms beyond PCs and phones and into connected homes.\nWhen you put all those pieces together, you'll realize Facebook's smartwatch could be used to enhance control of its VR and AR devices, or to expand its social networks into the Internet of Things (IoT) and perhaps succeed where the Portal failed. Facebook could also eventually upgrade its watches with CTRL-Labs' technologies and enable users to control other IoT devices with their minds.\nBut let's not get ahead of ourselves... yet\nFacebook has reportedly spent about $1 billion on the development of its smartwatch over the past few years, but it only initially plans to ship volumes in the low six figures.\nThat would make Facebook a tiny smartwatch maker compared to Apple (NASDAQ:AAPL), which grew its Apple Watch shipments 19% to 33.9 million in 2020, according to Counterpoint Research. Apple ended the year with a whopping 40% share of the global smartwatch market.\nFacebook likely realizes its smartwatch will face the same three problems that plagued the Portal: a deep distrust of Facebook's brand, privacy concerns, and its late arrival into a saturated market. Google also encountered similar criticisms after its recent takeover of Fitbit.\nFacebook reportedly plans to launch its smartwatch next summer for about $400. But a lot could happen within the next year, and new smartwatches -- including a new version of the Apple Watch -- could easily steal Facebook's thunder. A smartwatch with two cameras could also be considered complicated and redundant, especially when smartphones and action cameras serve the same purposes.\nThe key takeaways\nThe global smartwatch market could still grow from $59 billion this year to nearly $100 billion in 2025, according to Research and Markets. That's great news for Apple, but it also suggests the market might still be big enough for newcomers like Facebook to gain a foothold.\nBut investors should take all these rumors with a grain of salt until Facebook actually makes an official announcement. Even if Facebook's smartwatch fares better than the Portal, it probably won't generate a meaningful percentage of its revenue or reduce its overall dependence on ads.\nInstead, it should be considered a potential expansion of its ecosystem beyond PCs and phones, which might just complement its ongoing push into the virtual and augmented reality markets.","news_type":1},"isVote":1,"tweetType":1,"viewCount":904,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":163328074,"gmtCreate":1623860099598,"gmtModify":1634026869600,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163328074","repostId":"2143978737","repostType":4,"repost":{"id":"2143978737","pubTimestamp":1623857100,"share":"https://www.laohu8.com/m/news/2143978737?lang=&edition=full","pubTime":"2021-06-16 23:25","market":"us","language":"en","title":"Facebook's Hardware Business Is Creeping Into Apple's Backyard","url":"https://stock-news.laohu8.com/highlight/detail?id=2143978737","media":"Motley Fool","summary":"But Apple shouldn't lose any sleep over Facebook's smartwatch plans.","content":"<p><b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b> (NASDAQ:FB) could be developing a smartwatch with two cameras, according to The Verge. The camera on the front will likely be used for video calls, while the rear camera can be detached to capture photos and videos for Facebook's family of apps.</p>\n<p>Facebook is also reportedly in talks with companies to develop accessories for attaching the camera to backpacks and other objects. Previous rumors regarding the watch suggested it will sport health-tracking features, run on a stand-alone cellular connection, and use a custom version of the Android operating system. Could this long-rumored device help Facebook challenge <b>Apple</b> (NASDAQ:AAPL) in the smartwatch market?</p>\n<h2>Why is Facebook developing a smartwatch?</h2>\n<p>Facebook generated 97% of its revenue from ads last quarter. The remaining 3% came from its \"other\" businesses, which include its Oculus virtual reality (VR) headsets and Portal smart screens. It might initially seem odd for Facebook to add a smartwatch to that lineup, but it would actually complement its previous hardware strategies.</p>\n<p>Facebook's strongest hardware business is its lineup of Oculus VR headsets. It could ship at least three million Oculus Quest 2 headsets this year, according to SuperData. That would make the stand-alone VR headset, which doesn't require a PC or phone, the clear leader of its niche market.</p>\n<p>Looking beyond VR devices, Facebook is developing augmented reality (AR) glasses that will use similar controls as its Oculus headsets. It also acquired CTRL-Labs, which is developing a wristband that can use brain signals to control computers, in late 2019. In theory, CTRL-Labs' technology could eventually enable users to control VR and AR devices with \"mind-reading\" wristbands instead of controllers in the future.</p>\n<p>Meanwhile, Facebook's Portal devices haven't gained much momentum against <b>Amazon</b> (NASDAQ:AMZN) or <b>Alphabet</b>'s (NASDAQ:GOOGL) (NASDAQ:GOOG) Google in the smart screen market. That failure likely dashed Facebook's hopes of expanding its social networking platforms beyond PCs and phones and into connected homes.</p>\n<p>When you put all those pieces together, you'll realize Facebook's smartwatch could be used to enhance control of its VR and AR devices, or to expand its social networks into the Internet of Things (IoT) and perhaps succeed where the Portal failed. Facebook could also eventually upgrade its watches with CTRL-Labs' technologies and enable users to control other IoT devices with their minds.</p>\n<h2>But let's not get ahead of ourselves... yet</h2>\n<p>Facebook has reportedly spent about $1 billion on the development of its smartwatch over the past few years, but it only initially plans to ship volumes in the low six figures.</p>\n<p>That would make Facebook a tiny smartwatch maker compared to <b>Apple</b> (NASDAQ:AAPL), which grew its Apple Watch shipments 19% to 33.9 million in 2020, according to Counterpoint Research. Apple ended the year with a whopping 40% share of the global smartwatch market.</p>\n<p>Facebook likely realizes its smartwatch will face the same three problems that plagued the Portal: a deep distrust of Facebook's brand, privacy concerns, and its late arrival into a saturated market. Google also encountered similar criticisms after its recent takeover of Fitbit.</p>\n<p>Facebook reportedly plans to launch its smartwatch next summer for about $400. But a lot could happen within the next year, and new smartwatches -- including a new version of the Apple Watch -- could easily steal Facebook's thunder. A smartwatch with two cameras could also be considered complicated and redundant, especially when smartphones and action cameras serve the same purposes.</p>\n<h2>The key takeaways</h2>\n<p>The global smartwatch market could still grow from $59 billion this year to nearly $100 billion in 2025, according to Research and Markets. That's great news for Apple, but it also suggests the market might still be big enough for newcomers like Facebook to gain a foothold.</p>\n<p>But investors should take all these rumors with a grain of salt until Facebook actually makes an official announcement. Even if Facebook's smartwatch fares better than the Portal, it probably won't generate a meaningful percentage of its revenue or reduce its overall dependence on ads.</p>\n<p>Instead, it should be considered a potential expansion of its ecosystem beyond PCs and phones, which might just complement its ongoing push into the virtual and augmented reality markets.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Facebook's Hardware Business Is Creeping Into Apple's Backyard</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFacebook's Hardware Business Is Creeping Into Apple's Backyard\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 23:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/16/facebooks-hardware-business-is-creeping-into-apple/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Facebook (NASDAQ:FB) could be developing a smartwatch with two cameras, according to The Verge. The camera on the front will likely be used for video calls, while the rear camera can be detached to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/16/facebooks-hardware-business-is-creeping-into-apple/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09086":"华夏纳指-U","AAPL":"苹果","03086":"华夏纳指"},"source_url":"https://www.fool.com/investing/2021/06/16/facebooks-hardware-business-is-creeping-into-apple/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143978737","content_text":"Facebook (NASDAQ:FB) could be developing a smartwatch with two cameras, according to The Verge. The camera on the front will likely be used for video calls, while the rear camera can be detached to capture photos and videos for Facebook's family of apps.\nFacebook is also reportedly in talks with companies to develop accessories for attaching the camera to backpacks and other objects. Previous rumors regarding the watch suggested it will sport health-tracking features, run on a stand-alone cellular connection, and use a custom version of the Android operating system. Could this long-rumored device help Facebook challenge Apple (NASDAQ:AAPL) in the smartwatch market?\nWhy is Facebook developing a smartwatch?\nFacebook generated 97% of its revenue from ads last quarter. The remaining 3% came from its \"other\" businesses, which include its Oculus virtual reality (VR) headsets and Portal smart screens. It might initially seem odd for Facebook to add a smartwatch to that lineup, but it would actually complement its previous hardware strategies.\nFacebook's strongest hardware business is its lineup of Oculus VR headsets. It could ship at least three million Oculus Quest 2 headsets this year, according to SuperData. That would make the stand-alone VR headset, which doesn't require a PC or phone, the clear leader of its niche market.\nLooking beyond VR devices, Facebook is developing augmented reality (AR) glasses that will use similar controls as its Oculus headsets. It also acquired CTRL-Labs, which is developing a wristband that can use brain signals to control computers, in late 2019. In theory, CTRL-Labs' technology could eventually enable users to control VR and AR devices with \"mind-reading\" wristbands instead of controllers in the future.\nMeanwhile, Facebook's Portal devices haven't gained much momentum against Amazon (NASDAQ:AMZN) or Alphabet's (NASDAQ:GOOGL) (NASDAQ:GOOG) Google in the smart screen market. That failure likely dashed Facebook's hopes of expanding its social networking platforms beyond PCs and phones and into connected homes.\nWhen you put all those pieces together, you'll realize Facebook's smartwatch could be used to enhance control of its VR and AR devices, or to expand its social networks into the Internet of Things (IoT) and perhaps succeed where the Portal failed. Facebook could also eventually upgrade its watches with CTRL-Labs' technologies and enable users to control other IoT devices with their minds.\nBut let's not get ahead of ourselves... yet\nFacebook has reportedly spent about $1 billion on the development of its smartwatch over the past few years, but it only initially plans to ship volumes in the low six figures.\nThat would make Facebook a tiny smartwatch maker compared to Apple (NASDAQ:AAPL), which grew its Apple Watch shipments 19% to 33.9 million in 2020, according to Counterpoint Research. Apple ended the year with a whopping 40% share of the global smartwatch market.\nFacebook likely realizes its smartwatch will face the same three problems that plagued the Portal: a deep distrust of Facebook's brand, privacy concerns, and its late arrival into a saturated market. Google also encountered similar criticisms after its recent takeover of Fitbit.\nFacebook reportedly plans to launch its smartwatch next summer for about $400. But a lot could happen within the next year, and new smartwatches -- including a new version of the Apple Watch -- could easily steal Facebook's thunder. A smartwatch with two cameras could also be considered complicated and redundant, especially when smartphones and action cameras serve the same purposes.\nThe key takeaways\nThe global smartwatch market could still grow from $59 billion this year to nearly $100 billion in 2025, according to Research and Markets. That's great news for Apple, but it also suggests the market might still be big enough for newcomers like Facebook to gain a foothold.\nBut investors should take all these rumors with a grain of salt until Facebook actually makes an official announcement. Even if Facebook's smartwatch fares better than the Portal, it probably won't generate a meaningful percentage of its revenue or reduce its overall dependence on ads.\nInstead, it should be considered a potential expansion of its ecosystem beyond PCs and phones, which might just complement its ongoing push into the virtual and augmented reality markets.","news_type":1},"isVote":1,"tweetType":1,"viewCount":328,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":846797989,"gmtCreate":1636112138356,"gmtModify":1636112280599,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Will Pfizer for once pfi(fly) up to the moon?&nbsp;[财迷]&nbsp;","listText":"Will Pfizer for once pfi(fly) up to the moon?&nbsp;[财迷]&nbsp;","text":"Will Pfizer for once pfi(fly) up to the moon? [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/846797989","repostId":"1168526565","repostType":2,"repost":{"id":"1168526565","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636109309,"share":"https://www.laohu8.com/m/news/1168526565?lang=&edition=full","pubTime":"2021-11-05 18:48","market":"us","language":"en","title":"Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168526565","media":"Tiger Newspress","summary":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug wa","content":"<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p>\n<p>The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p>\n<p>Full trial data is not yet available from either company.</p>\n<p>Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p>\n<p>The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p>\n<p>The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p>\n<p>It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p>\n<p>Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p>\n<p>Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p>\n<p>\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p>\n<p>The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p>\n<p>\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p>\n<p>Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p>\n<p>Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p>\n<p>Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p>\n<p>Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p>\n<p>Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p>\n<p>Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-05 18:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p>\n<p>The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p>\n<p>Full trial data is not yet available from either company.</p>\n<p>Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p>\n<p>The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p>\n<p>The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p>\n<p>It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p>\n<p>Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p>\n<p>Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p>\n<p>\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p>\n<p>The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p>\n<p>\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p>\n<p>Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p>\n<p>Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p>\n<p>Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p>\n<p>Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p>\n<p>Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p>\n<p>Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168526565","content_text":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.\nThe results appear to surpass those seen with Merck & Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.\nFull trial data is not yet available from either company.\nPfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.\nThe combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.\nThe planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.\nIt found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.\nRates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.\nAntivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.\n\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.\nThe company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.\n\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.\nInfectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.\nPfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.\nMerck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.\nBritain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.\nPfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.\nIts shares rose over 9% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":942,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846798097,"gmtCreate":1636111622666,"gmtModify":1636111622737,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Omg that's good news!&nbsp;","listText":"Omg that's good news!&nbsp;","text":"Omg that's good news!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846798097","repostId":"1168526565","repostType":2,"repost":{"id":"1168526565","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636109309,"share":"https://www.laohu8.com/m/news/1168526565?lang=&edition=full","pubTime":"2021-11-05 18:48","market":"us","language":"en","title":"Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168526565","media":"Tiger Newspress","summary":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug wa","content":"<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p>\n<p>The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p>\n<p>Full trial data is not yet available from either company.</p>\n<p>Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p>\n<p>The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p>\n<p>The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p>\n<p>It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p>\n<p>Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p>\n<p>Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p>\n<p>\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p>\n<p>The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p>\n<p>\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p>\n<p>Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p>\n<p>Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p>\n<p>Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p>\n<p>Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p>\n<p>Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p>\n<p>Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-05 18:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p>\n<p>The results appear to surpass those seen with Merck &amp; Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p>\n<p>Full trial data is not yet available from either company.</p>\n<p>Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p>\n<p>The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p>\n<p>The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p>\n<p>It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p>\n<p>Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p>\n<p>Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p>\n<p>\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p>\n<p>The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p>\n<p>\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p>\n<p>Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p>\n<p>Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p>\n<p>Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p>\n<p>Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p>\n<p>Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p>\n<p>Its&nbsp;shares&nbsp;rose&nbsp;over&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168526565","content_text":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.\nThe results appear to surpass those seen with Merck & Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.\nFull trial data is not yet available from either company.\nPfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.\nThe combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.\nThe planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.\nIt found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.\nRates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.\nAntivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.\n\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.\nThe company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.\n\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.\nInfectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.\nPfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.\nMerck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.\nBritain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.\nPfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.\nIts shares rose over 9% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1049,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600554198,"gmtCreate":1638178262115,"gmtModify":1638178262281,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Will tesla 🚀 to a whole new level?","listText":"Will tesla 🚀 to a whole new level?","text":"Will tesla 🚀 to a whole new level?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600554198","repostId":"1180553445","repostType":4,"repost":{"id":"1180553445","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638177356,"share":"https://www.laohu8.com/m/news/1180553445?lang=&edition=full","pubTime":"2021-11-29 17:15","market":"us","language":"en","title":"Tesla stock rallied nearly 3% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1180553445","media":"Tiger Newspress","summary":"Tesla stock rallied nearly 3% in premarket trading as it to start production in Germany in December,","content":"<p>Tesla stock rallied nearly&nbsp;3% in premarket trading&nbsp;as&nbsp;it to start production in Germany in December,according to&nbsp;Automobilwoche.</p>\n<p><img src=\"https://static.tigerbbs.com/c924dd7ad062e13f25605d196e86462b\" tg-width=\"853\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p>\n<p>Tesla Inc. will launch its overdue German production operations in December, Automobilwoche reported, estimating as many as 30,000 vehicles will be manufactured there in the first half of 2022.</p>\n<p>Production was to have begun in July but was delayed because the company hadn’t received environmental clearance. Local regulators are expected to grant the necessary permits within days, the magazine said, without reporting where it received its information.</p>\n<p>Five units of Model Y have already been completed at the Gigafactory near Berlin, though not on the production line. In January, serial production will start with 1,000 cars per week and gradually increase, according to Automobilwoche.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla stock rallied nearly 3% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla stock rallied nearly 3% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-29 17:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla stock rallied nearly&nbsp;3% in premarket trading&nbsp;as&nbsp;it to start production in Germany in December,according to&nbsp;Automobilwoche.</p>\n<p><img src=\"https://static.tigerbbs.com/c924dd7ad062e13f25605d196e86462b\" tg-width=\"853\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p>\n<p>Tesla Inc. will launch its overdue German production operations in December, Automobilwoche reported, estimating as many as 30,000 vehicles will be manufactured there in the first half of 2022.</p>\n<p>Production was to have begun in July but was delayed because the company hadn’t received environmental clearance. Local regulators are expected to grant the necessary permits within days, the magazine said, without reporting where it received its information.</p>\n<p>Five units of Model Y have already been completed at the Gigafactory near Berlin, though not on the production line. In January, serial production will start with 1,000 cars per week and gradually increase, according to Automobilwoche.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180553445","content_text":"Tesla stock rallied nearly 3% in premarket trading as it to start production in Germany in December,according to Automobilwoche.\n\nTesla Inc. will launch its overdue German production operations in December, Automobilwoche reported, estimating as many as 30,000 vehicles will be manufactured there in the first half of 2022.\nProduction was to have begun in July but was delayed because the company hadn’t received environmental clearance. Local regulators are expected to grant the necessary permits within days, the magazine said, without reporting where it received its information.\nFive units of Model Y have already been completed at the Gigafactory near Berlin, though not on the production line. In January, serial production will start with 1,000 cars per week and gradually increase, according to Automobilwoche.","news_type":1},"isVote":1,"tweetType":1,"viewCount":720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877561413,"gmtCreate":1637944348124,"gmtModify":1637944348124,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>&nbsp;awww where's the last hr sales","listText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>&nbsp;awww where's the last hr sales","text":"$Sea Ltd(SE)$ awww where's the last hr sales","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877561413","isVote":1,"tweetType":1,"viewCount":955,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853937233,"gmtCreate":1634755270098,"gmtModify":1634755270227,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Will&nbsp;<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>hit 900 alike earlier part of the year?&nbsp;","listText":"Will&nbsp;<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>hit 900 alike earlier part of the year?&nbsp;","text":"Will $Tesla Motors(TSLA)$hit 900 alike earlier part of the year?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853937233","isVote":1,"tweetType":1,"viewCount":687,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846711921,"gmtCreate":1636113379725,"gmtModify":1636113503105,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Buy the slid wheee","listText":"Buy the slid wheee","text":"Buy the slid wheee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846711921","repostId":"1136485403","repostType":2,"repost":{"id":"1136485403","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636099391,"share":"https://www.laohu8.com/m/news/1136485403?lang=&edition=full","pubTime":"2021-11-05 16:03","market":"us","language":"en","title":"Square stock slid 4% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1136485403","media":"Tiger Newspress","summary":"Square stock slid 4% in premarket trading after the digital-payments company reported disappointing ","content":"<p>Square stock slid 4% in premarket trading&nbsp;after&nbsp;the digital-payments company&nbsp;reported disappointing third-quarter sales, held back by a drop in Bitcoin-related revenue from its Cash App compared with the previous period.</p>\n<p><img src=\"https://static.tigerbbs.com/bb8ed5ad65de7047290ae40501a552c5\" tg-width=\"850\" tg-height=\"620\" width=\"100%\" height=\"auto\"></p>\n<p>Overall sales were $3.84 billion, up 27% from a year earlier but less than the average analyst estimate of $4.51 billion, according to data compiled by Bloomberg. Gross profit, which includes fees taken from Square’s Cash App and Seller businesses, was $1.13 billion in the period, an increase of 43% from a year earlier, but little changed compared with the second quarter.</p>\n<p>While revenue from sales of Bitcoin was $1.82 billion, representing 47% of Square’s total sales, those transactions contribute little to the company’s bottom line. Sales of the cryptocurrency generated just 3.7% of Square’s gross profit in the third quarter, the company said Thursday in a&nbsp;statement.</p>\n<p>Bitcoin transactions through Cash App have grown tremendously over the past two years, but Bitcoin revenue can be a deceiving metric. Square reports all Bitcoin sales as revenue, Chief Financial Officer Amrita Ahuja said, which is why that number can look very large and is dependent on things like price volatility. Bitcoin gross profit, though, represents the money Square collects via fees from Bitcoin transactions, and is a better reflection of that part of Square’s business, she added.</p>\n<p>Ahuja said the company is trying to build other products and features related to Bitcoin beyond buying and selling the currency. Chief Executive Officer Dorsey, who also runs Twitter Inc., is a major Bitcoin proponent, and tweets about the currency often. Square&nbsp;acquired $170 million&nbsp;worth of Bitcoin in February 2021.</p>\n<p>When asked whether Square plans to add the ability to buy other cryptocurrencies within Cash App, she said, “we’re focused on Bitcoin.”</p>\n<p>Square also expanded its Cash App offering to teenagers in October, a move that gives the company access to as many as 20 million teens in the U.S. alone, Ahuja said. Cash App had 40 million monthly customers in total as of June.</p>\n<p>“Those folks will represent a larger portion of spend in the coming years,” she said. “We can now meet an individual earlier on in their financial journey and grow with them over time.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Square stock slid 4% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSquare stock slid 4% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-05 16:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Square stock slid 4% in premarket trading&nbsp;after&nbsp;the digital-payments company&nbsp;reported disappointing third-quarter sales, held back by a drop in Bitcoin-related revenue from its Cash App compared with the previous period.</p>\n<p><img src=\"https://static.tigerbbs.com/bb8ed5ad65de7047290ae40501a552c5\" tg-width=\"850\" tg-height=\"620\" width=\"100%\" height=\"auto\"></p>\n<p>Overall sales were $3.84 billion, up 27% from a year earlier but less than the average analyst estimate of $4.51 billion, according to data compiled by Bloomberg. Gross profit, which includes fees taken from Square’s Cash App and Seller businesses, was $1.13 billion in the period, an increase of 43% from a year earlier, but little changed compared with the second quarter.</p>\n<p>While revenue from sales of Bitcoin was $1.82 billion, representing 47% of Square’s total sales, those transactions contribute little to the company’s bottom line. Sales of the cryptocurrency generated just 3.7% of Square’s gross profit in the third quarter, the company said Thursday in a&nbsp;statement.</p>\n<p>Bitcoin transactions through Cash App have grown tremendously over the past two years, but Bitcoin revenue can be a deceiving metric. Square reports all Bitcoin sales as revenue, Chief Financial Officer Amrita Ahuja said, which is why that number can look very large and is dependent on things like price volatility. Bitcoin gross profit, though, represents the money Square collects via fees from Bitcoin transactions, and is a better reflection of that part of Square’s business, she added.</p>\n<p>Ahuja said the company is trying to build other products and features related to Bitcoin beyond buying and selling the currency. Chief Executive Officer Dorsey, who also runs Twitter Inc., is a major Bitcoin proponent, and tweets about the currency often. Square&nbsp;acquired $170 million&nbsp;worth of Bitcoin in February 2021.</p>\n<p>When asked whether Square plans to add the ability to buy other cryptocurrencies within Cash App, she said, “we’re focused on Bitcoin.”</p>\n<p>Square also expanded its Cash App offering to teenagers in October, a move that gives the company access to as many as 20 million teens in the U.S. alone, Ahuja said. Cash App had 40 million monthly customers in total as of June.</p>\n<p>“Those folks will represent a larger portion of spend in the coming years,” she said. “We can now meet an individual earlier on in their financial journey and grow with them over time.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SQ":"Block"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136485403","content_text":"Square stock slid 4% in premarket trading after the digital-payments company reported disappointing third-quarter sales, held back by a drop in Bitcoin-related revenue from its Cash App compared with the previous period.\n\nOverall sales were $3.84 billion, up 27% from a year earlier but less than the average analyst estimate of $4.51 billion, according to data compiled by Bloomberg. Gross profit, which includes fees taken from Square’s Cash App and Seller businesses, was $1.13 billion in the period, an increase of 43% from a year earlier, but little changed compared with the second quarter.\nWhile revenue from sales of Bitcoin was $1.82 billion, representing 47% of Square’s total sales, those transactions contribute little to the company’s bottom line. Sales of the cryptocurrency generated just 3.7% of Square’s gross profit in the third quarter, the company said Thursday in a statement.\nBitcoin transactions through Cash App have grown tremendously over the past two years, but Bitcoin revenue can be a deceiving metric. Square reports all Bitcoin sales as revenue, Chief Financial Officer Amrita Ahuja said, which is why that number can look very large and is dependent on things like price volatility. Bitcoin gross profit, though, represents the money Square collects via fees from Bitcoin transactions, and is a better reflection of that part of Square’s business, she added.\nAhuja said the company is trying to build other products and features related to Bitcoin beyond buying and selling the currency. Chief Executive Officer Dorsey, who also runs Twitter Inc., is a major Bitcoin proponent, and tweets about the currency often. Square acquired $170 million worth of Bitcoin in February 2021.\nWhen asked whether Square plans to add the ability to buy other cryptocurrencies within Cash App, she said, “we’re focused on Bitcoin.”\nSquare also expanded its Cash App offering to teenagers in October, a move that gives the company access to as many as 20 million teens in the U.S. alone, Ahuja said. Cash App had 40 million monthly customers in total as of June.\n“Those folks will represent a larger portion of spend in the coming years,” she said. “We can now meet an individual earlier on in their financial journey and grow with them over time.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":745,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":128865013,"gmtCreate":1624510533832,"gmtModify":1634005038213,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128865013","repostId":"1170004118","repostType":4,"repost":{"id":"1170004118","pubTimestamp":1624491924,"share":"https://www.laohu8.com/m/news/1170004118?lang=&edition=full","pubTime":"2021-06-24 07:45","market":"us","language":"en","title":"Cathie Wood bought 1 million shares of Grayscale Bitcoin Trust during crypto's drop below $30,000","url":"https://stock-news.laohu8.com/highlight/detail?id=1170004118","media":"CNBC","summary":"Ark Invest’s Cathie Wood took advantage of the volatility in bitcoin on Tuesday, buying up shares of","content":"<div>\n<p>Ark Invest’s Cathie Wood took advantage of the volatility in bitcoin on Tuesday, buying up shares of Grayscale Bitcoin Trust and Coinbase.\nWood — known for taking advantage of dips in her highest ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/23/cathie-wood-bought-1-million-shares-of-the-grayscale-bitcoin-trust-during-drop-below-30000.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood bought 1 million shares of Grayscale Bitcoin Trust during crypto's drop below $30,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood bought 1 million shares of Grayscale Bitcoin Trust during crypto's drop below $30,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 07:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/23/cathie-wood-bought-1-million-shares-of-the-grayscale-bitcoin-trust-during-drop-below-30000.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ark Invest’s Cathie Wood took advantage of the volatility in bitcoin on Tuesday, buying up shares of Grayscale Bitcoin Trust and Coinbase.\nWood — known for taking advantage of dips in her highest ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/23/cathie-wood-bought-1-million-shares-of-the-grayscale-bitcoin-trust-during-drop-below-30000.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc.","GBTC":"Grayscale Bitcoin Trust"},"source_url":"https://www.cnbc.com/2021/06/23/cathie-wood-bought-1-million-shares-of-the-grayscale-bitcoin-trust-during-drop-below-30000.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1170004118","content_text":"Ark Invest’s Cathie Wood took advantage of the volatility in bitcoin on Tuesday, buying up shares of Grayscale Bitcoin Trust and Coinbase.\nWood — known for taking advantage of dips in her highest conviction picks —purchased 1,046,002 shares of the Grayscale Bitcoin Trust in theARK Next Generation Internet ETFon Tuesday, a position worth roughly $29 million based on Grayscale’s closing price of $28.01 per share. Shares of Grayscale closed flat on Tuesday but dropped near $25 per share during the rout in bitcoin.\nThe founder and CEO of Ark Invest also purchased 214,718 shares of Coinbase in her flagship fundARK Innovationfund, worth about $47.8 million based on Coinbase’s closing price of $222.47 per share. Shares of Coinbase closed down just 0.6% on Tuesday, but the stock dropped as low as $210 per share during the trading day.\n\nThe price of bitcoin tumbled below the key $30,000 level Tuesday morning and then rallied back into positive territory in a wild reversal. Near its low of the day, bitcoin fell more than 11% to about $28,911, below the $29,026 level where it ended 2020, according to Coin Metrics. The cryptocurrency then bounced and traded around $32,637.54 around the market close.\nWith Tuesday’s losses, bitcoin has been cut in half from its all-time high of more than $64,000 in mid-April. Bitcoin last traded up 4% to around $33,958, according to Coin Metrics.\nGrayscale Bitcoin Trust, an investment that holds bitcoin, is now the 7th largest holding in ARK Next Generation Internet ETF, representing more than 4% of the fund. The trust is down 12% this year but up over 150% over the last 12 months.\n\nMeanwhile, Coinbase, the world’s largest cryptocurrency exchange, is the 10th largest holding in Ark’s flagship fund ARK Innovation. The stock represents nearly 3.5% of the ETF.\n\nThe Ark fund’s prospectus states it may have indirect exposure to bitcoin through the Grayscale trust but not through bitcoin itself.","news_type":1},"isVote":1,"tweetType":1,"viewCount":129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128868955,"gmtCreate":1624510444177,"gmtModify":1634005040737,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Bbtea ❤️","listText":"Bbtea ❤️","text":"Bbtea ❤️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128868955","repostId":"1178700711","repostType":4,"repost":{"id":"1178700711","pubTimestamp":1624497882,"share":"https://www.laohu8.com/m/news/1178700711?lang=&edition=full","pubTime":"2021-06-24 09:24","market":"hk","language":"en","title":"Bubble Tea Chain Raises $656 Million in Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1178700711","media":"Bloomberg","summary":"(Bloomberg) -- Chinese bubble tea chain Nayuki Holdings Ltd. has raised HK$5.09 billion ($656 millio","content":"<p>(Bloomberg) -- Chinese bubble tea chain Nayuki Holdings Ltd. has raised HK$5.09 billion ($656 million) after pricing its Hong Kong initial public offering at the top of a marketed range, the latest company to ride a resurgence of listings in the Asian financial hub.</p>\n<p>Nayuki, whose popular fresh-fruit teas include cheese-foam-topped beverages, has priced 257.3 million shares at HK$19.8 each, according to terms of the deal obtained by Bloomberg News. It had marketed the shares at HK$17.2 to HK$19.8 apiece.</p>\n<p>The teahouse operator is testing the waters after Angelalign Technology Inc., a maker of clear orthodontic braces, heralded a revival in Hong Kong’s IPO market with a massive 132% pop on its June 16 debut, becoming one of this year’s most popular offerings in the city.</p>\n<p>First-time share sales in Hong Kong are ticking up after a period of muted activity, as an easing of the global tech selloff has created a more favorable backdrop for debuts. At least 13 companies are currently in the lineup to go public, compared to only two deals priced in April and four in May, according to data compiled by Bloomberg.</p>\n<p>Still, not every IPO is getting a warm welcome as investors have become more selective amid higher volatility in markets and growing expectations of a tightening of U.S. monetary policy. China Youran Dairy Group Ltd. and CARsgen Therapeutics Holdings Ltd. slumped 12% and 9%, respectively, in their trading debuts last Friday.</p>\n<p>Nayuki’s share sale attracted five cornerstone investors who agreed to subscribe for about $155 million of stock. They are UBS Asset Management, China Universal Asset Management, GF Fund, China Southern Asset Management and CCB International, according to the prospectus.</p>\n<p>The retail portion of Nayuki’s IPO was more than 400 times oversubscribed, the Hong Kong Economic Journal reported, citing people it didn’t identify.</p>\n<p>The top-of-the-range pricing values the bubble tea chain at about $4.38 billion, up from the $2 billion in its last funding round. It originally planned to file for an IPO in the U.S. in February last year, Bloomberg News reported, but eventually opted for Hong Kong.</p>\n<p>The Shenzhen-based firm sells fresh-fruit teas, cold-brew beverages and baked goods. It recorded losses of 203 million yuan in 2020 and 40 million yuan in the previous year, according to its prospectus. Revenue rose 22% year-on-year to 3.1 billion yuan.</p>\n<p>Nayuki plans to use proceeds from the offering to expand its teahouse network, deepen market penetration and strengthen its supply chain. It had 491 flagship Nayuki outlets at the end of last year, including 489 in mainland China and one each in Hong Kong and Japan.</p>\n<p>Nayuki’s shares are set to start trading in Hong Kong on June 30. JPMorgan Chase &amp; Co., CMB International Capital Ltd. and Huatai International Ltd. are joint sponsors for the listing.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bubble Tea Chain Raises $656 Million in Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBubble Tea Chain Raises $656 Million in Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 09:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bubble-tea-chain-said-raise-111206490.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Chinese bubble tea chain Nayuki Holdings Ltd. has raised HK$5.09 billion ($656 million) after pricing its Hong Kong initial public offering at the top of a marketed range, the latest ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bubble-tea-chain-said-raise-111206490.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02150":"奈雪的茶"},"source_url":"https://finance.yahoo.com/news/bubble-tea-chain-said-raise-111206490.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178700711","content_text":"(Bloomberg) -- Chinese bubble tea chain Nayuki Holdings Ltd. has raised HK$5.09 billion ($656 million) after pricing its Hong Kong initial public offering at the top of a marketed range, the latest company to ride a resurgence of listings in the Asian financial hub.\nNayuki, whose popular fresh-fruit teas include cheese-foam-topped beverages, has priced 257.3 million shares at HK$19.8 each, according to terms of the deal obtained by Bloomberg News. It had marketed the shares at HK$17.2 to HK$19.8 apiece.\nThe teahouse operator is testing the waters after Angelalign Technology Inc., a maker of clear orthodontic braces, heralded a revival in Hong Kong’s IPO market with a massive 132% pop on its June 16 debut, becoming one of this year’s most popular offerings in the city.\nFirst-time share sales in Hong Kong are ticking up after a period of muted activity, as an easing of the global tech selloff has created a more favorable backdrop for debuts. At least 13 companies are currently in the lineup to go public, compared to only two deals priced in April and four in May, according to data compiled by Bloomberg.\nStill, not every IPO is getting a warm welcome as investors have become more selective amid higher volatility in markets and growing expectations of a tightening of U.S. monetary policy. China Youran Dairy Group Ltd. and CARsgen Therapeutics Holdings Ltd. slumped 12% and 9%, respectively, in their trading debuts last Friday.\nNayuki’s share sale attracted five cornerstone investors who agreed to subscribe for about $155 million of stock. They are UBS Asset Management, China Universal Asset Management, GF Fund, China Southern Asset Management and CCB International, according to the prospectus.\nThe retail portion of Nayuki’s IPO was more than 400 times oversubscribed, the Hong Kong Economic Journal reported, citing people it didn’t identify.\nThe top-of-the-range pricing values the bubble tea chain at about $4.38 billion, up from the $2 billion in its last funding round. It originally planned to file for an IPO in the U.S. in February last year, Bloomberg News reported, but eventually opted for Hong Kong.\nThe Shenzhen-based firm sells fresh-fruit teas, cold-brew beverages and baked goods. It recorded losses of 203 million yuan in 2020 and 40 million yuan in the previous year, according to its prospectus. Revenue rose 22% year-on-year to 3.1 billion yuan.\nNayuki plans to use proceeds from the offering to expand its teahouse network, deepen market penetration and strengthen its supply chain. It had 491 flagship Nayuki outlets at the end of last year, including 489 in mainland China and one each in Hong Kong and Japan.\nNayuki’s shares are set to start trading in Hong Kong on June 30. JPMorgan Chase & Co., CMB International Capital Ltd. and Huatai International Ltd. are joint sponsors for the listing.","news_type":1},"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163327019,"gmtCreate":1623860210331,"gmtModify":1634026865490,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Wow[得意]&nbsp;","listText":"Wow[得意]&nbsp;","text":"Wow[得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163327019","repostId":"2143978737","repostType":4,"repost":{"id":"2143978737","pubTimestamp":1623857100,"share":"https://www.laohu8.com/m/news/2143978737?lang=&edition=full","pubTime":"2021-06-16 23:25","market":"us","language":"en","title":"Facebook's Hardware Business Is Creeping Into Apple's Backyard","url":"https://stock-news.laohu8.com/highlight/detail?id=2143978737","media":"Motley Fool","summary":"But Apple shouldn't lose any sleep over Facebook's smartwatch plans.","content":"<p><b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b> (NASDAQ:FB) could be developing a smartwatch with two cameras, according to The Verge. The camera on the front will likely be used for video calls, while the rear camera can be detached to capture photos and videos for Facebook's family of apps.</p>\n<p>Facebook is also reportedly in talks with companies to develop accessories for attaching the camera to backpacks and other objects. Previous rumors regarding the watch suggested it will sport health-tracking features, run on a stand-alone cellular connection, and use a custom version of the Android operating system. Could this long-rumored device help Facebook challenge <b>Apple</b> (NASDAQ:AAPL) in the smartwatch market?</p>\n<h2>Why is Facebook developing a smartwatch?</h2>\n<p>Facebook generated 97% of its revenue from ads last quarter. The remaining 3% came from its \"other\" businesses, which include its Oculus virtual reality (VR) headsets and Portal smart screens. It might initially seem odd for Facebook to add a smartwatch to that lineup, but it would actually complement its previous hardware strategies.</p>\n<p>Facebook's strongest hardware business is its lineup of Oculus VR headsets. It could ship at least three million Oculus Quest 2 headsets this year, according to SuperData. That would make the stand-alone VR headset, which doesn't require a PC or phone, the clear leader of its niche market.</p>\n<p>Looking beyond VR devices, Facebook is developing augmented reality (AR) glasses that will use similar controls as its Oculus headsets. It also acquired CTRL-Labs, which is developing a wristband that can use brain signals to control computers, in late 2019. In theory, CTRL-Labs' technology could eventually enable users to control VR and AR devices with \"mind-reading\" wristbands instead of controllers in the future.</p>\n<p>Meanwhile, Facebook's Portal devices haven't gained much momentum against <b>Amazon</b> (NASDAQ:AMZN) or <b>Alphabet</b>'s (NASDAQ:GOOGL) (NASDAQ:GOOG) Google in the smart screen market. That failure likely dashed Facebook's hopes of expanding its social networking platforms beyond PCs and phones and into connected homes.</p>\n<p>When you put all those pieces together, you'll realize Facebook's smartwatch could be used to enhance control of its VR and AR devices, or to expand its social networks into the Internet of Things (IoT) and perhaps succeed where the Portal failed. Facebook could also eventually upgrade its watches with CTRL-Labs' technologies and enable users to control other IoT devices with their minds.</p>\n<h2>But let's not get ahead of ourselves... yet</h2>\n<p>Facebook has reportedly spent about $1 billion on the development of its smartwatch over the past few years, but it only initially plans to ship volumes in the low six figures.</p>\n<p>That would make Facebook a tiny smartwatch maker compared to <b>Apple</b> (NASDAQ:AAPL), which grew its Apple Watch shipments 19% to 33.9 million in 2020, according to Counterpoint Research. Apple ended the year with a whopping 40% share of the global smartwatch market.</p>\n<p>Facebook likely realizes its smartwatch will face the same three problems that plagued the Portal: a deep distrust of Facebook's brand, privacy concerns, and its late arrival into a saturated market. Google also encountered similar criticisms after its recent takeover of Fitbit.</p>\n<p>Facebook reportedly plans to launch its smartwatch next summer for about $400. But a lot could happen within the next year, and new smartwatches -- including a new version of the Apple Watch -- could easily steal Facebook's thunder. A smartwatch with two cameras could also be considered complicated and redundant, especially when smartphones and action cameras serve the same purposes.</p>\n<h2>The key takeaways</h2>\n<p>The global smartwatch market could still grow from $59 billion this year to nearly $100 billion in 2025, according to Research and Markets. That's great news for Apple, but it also suggests the market might still be big enough for newcomers like Facebook to gain a foothold.</p>\n<p>But investors should take all these rumors with a grain of salt until Facebook actually makes an official announcement. Even if Facebook's smartwatch fares better than the Portal, it probably won't generate a meaningful percentage of its revenue or reduce its overall dependence on ads.</p>\n<p>Instead, it should be considered a potential expansion of its ecosystem beyond PCs and phones, which might just complement its ongoing push into the virtual and augmented reality markets.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Facebook's Hardware Business Is Creeping Into Apple's Backyard</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFacebook's Hardware Business Is Creeping Into Apple's Backyard\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 23:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/16/facebooks-hardware-business-is-creeping-into-apple/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Facebook (NASDAQ:FB) could be developing a smartwatch with two cameras, according to The Verge. The camera on the front will likely be used for video calls, while the rear camera can be detached to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/16/facebooks-hardware-business-is-creeping-into-apple/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09086":"华夏纳指-U","AAPL":"苹果","03086":"华夏纳指"},"source_url":"https://www.fool.com/investing/2021/06/16/facebooks-hardware-business-is-creeping-into-apple/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143978737","content_text":"Facebook (NASDAQ:FB) could be developing a smartwatch with two cameras, according to The Verge. The camera on the front will likely be used for video calls, while the rear camera can be detached to capture photos and videos for Facebook's family of apps.\nFacebook is also reportedly in talks with companies to develop accessories for attaching the camera to backpacks and other objects. Previous rumors regarding the watch suggested it will sport health-tracking features, run on a stand-alone cellular connection, and use a custom version of the Android operating system. Could this long-rumored device help Facebook challenge Apple (NASDAQ:AAPL) in the smartwatch market?\nWhy is Facebook developing a smartwatch?\nFacebook generated 97% of its revenue from ads last quarter. The remaining 3% came from its \"other\" businesses, which include its Oculus virtual reality (VR) headsets and Portal smart screens. It might initially seem odd for Facebook to add a smartwatch to that lineup, but it would actually complement its previous hardware strategies.\nFacebook's strongest hardware business is its lineup of Oculus VR headsets. It could ship at least three million Oculus Quest 2 headsets this year, according to SuperData. That would make the stand-alone VR headset, which doesn't require a PC or phone, the clear leader of its niche market.\nLooking beyond VR devices, Facebook is developing augmented reality (AR) glasses that will use similar controls as its Oculus headsets. It also acquired CTRL-Labs, which is developing a wristband that can use brain signals to control computers, in late 2019. In theory, CTRL-Labs' technology could eventually enable users to control VR and AR devices with \"mind-reading\" wristbands instead of controllers in the future.\nMeanwhile, Facebook's Portal devices haven't gained much momentum against Amazon (NASDAQ:AMZN) or Alphabet's (NASDAQ:GOOGL) (NASDAQ:GOOG) Google in the smart screen market. That failure likely dashed Facebook's hopes of expanding its social networking platforms beyond PCs and phones and into connected homes.\nWhen you put all those pieces together, you'll realize Facebook's smartwatch could be used to enhance control of its VR and AR devices, or to expand its social networks into the Internet of Things (IoT) and perhaps succeed where the Portal failed. Facebook could also eventually upgrade its watches with CTRL-Labs' technologies and enable users to control other IoT devices with their minds.\nBut let's not get ahead of ourselves... yet\nFacebook has reportedly spent about $1 billion on the development of its smartwatch over the past few years, but it only initially plans to ship volumes in the low six figures.\nThat would make Facebook a tiny smartwatch maker compared to Apple (NASDAQ:AAPL), which grew its Apple Watch shipments 19% to 33.9 million in 2020, according to Counterpoint Research. Apple ended the year with a whopping 40% share of the global smartwatch market.\nFacebook likely realizes its smartwatch will face the same three problems that plagued the Portal: a deep distrust of Facebook's brand, privacy concerns, and its late arrival into a saturated market. Google also encountered similar criticisms after its recent takeover of Fitbit.\nFacebook reportedly plans to launch its smartwatch next summer for about $400. But a lot could happen within the next year, and new smartwatches -- including a new version of the Apple Watch -- could easily steal Facebook's thunder. A smartwatch with two cameras could also be considered complicated and redundant, especially when smartphones and action cameras serve the same purposes.\nThe key takeaways\nThe global smartwatch market could still grow from $59 billion this year to nearly $100 billion in 2025, according to Research and Markets. That's great news for Apple, but it also suggests the market might still be big enough for newcomers like Facebook to gain a foothold.\nBut investors should take all these rumors with a grain of salt until Facebook actually makes an official announcement. Even if Facebook's smartwatch fares better than the Portal, it probably won't generate a meaningful percentage of its revenue or reduce its overall dependence on ads.\nInstead, it should be considered a potential expansion of its ecosystem beyond PCs and phones, which might just complement its ongoing push into the virtual and augmented reality markets.","news_type":1},"isVote":1,"tweetType":1,"viewCount":904,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":163328074,"gmtCreate":1623860099598,"gmtModify":1634026869600,"author":{"id":"3574940915326235","authorId":"3574940915326235","name":"TheMysTrader","avatar":"https://static.tigerbbs.com/08abc512620038ac153ab0bf62705216","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574940915326235","idStr":"3574940915326235"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163328074","repostId":"2143978737","repostType":4,"repost":{"id":"2143978737","pubTimestamp":1623857100,"share":"https://www.laohu8.com/m/news/2143978737?lang=&edition=full","pubTime":"2021-06-16 23:25","market":"us","language":"en","title":"Facebook's Hardware Business Is Creeping Into Apple's Backyard","url":"https://stock-news.laohu8.com/highlight/detail?id=2143978737","media":"Motley Fool","summary":"But Apple shouldn't lose any sleep over Facebook's smartwatch plans.","content":"<p><b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b> (NASDAQ:FB) could be developing a smartwatch with two cameras, according to The Verge. The camera on the front will likely be used for video calls, while the rear camera can be detached to capture photos and videos for Facebook's family of apps.</p>\n<p>Facebook is also reportedly in talks with companies to develop accessories for attaching the camera to backpacks and other objects. Previous rumors regarding the watch suggested it will sport health-tracking features, run on a stand-alone cellular connection, and use a custom version of the Android operating system. Could this long-rumored device help Facebook challenge <b>Apple</b> (NASDAQ:AAPL) in the smartwatch market?</p>\n<h2>Why is Facebook developing a smartwatch?</h2>\n<p>Facebook generated 97% of its revenue from ads last quarter. The remaining 3% came from its \"other\" businesses, which include its Oculus virtual reality (VR) headsets and Portal smart screens. It might initially seem odd for Facebook to add a smartwatch to that lineup, but it would actually complement its previous hardware strategies.</p>\n<p>Facebook's strongest hardware business is its lineup of Oculus VR headsets. It could ship at least three million Oculus Quest 2 headsets this year, according to SuperData. That would make the stand-alone VR headset, which doesn't require a PC or phone, the clear leader of its niche market.</p>\n<p>Looking beyond VR devices, Facebook is developing augmented reality (AR) glasses that will use similar controls as its Oculus headsets. It also acquired CTRL-Labs, which is developing a wristband that can use brain signals to control computers, in late 2019. In theory, CTRL-Labs' technology could eventually enable users to control VR and AR devices with \"mind-reading\" wristbands instead of controllers in the future.</p>\n<p>Meanwhile, Facebook's Portal devices haven't gained much momentum against <b>Amazon</b> (NASDAQ:AMZN) or <b>Alphabet</b>'s (NASDAQ:GOOGL) (NASDAQ:GOOG) Google in the smart screen market. That failure likely dashed Facebook's hopes of expanding its social networking platforms beyond PCs and phones and into connected homes.</p>\n<p>When you put all those pieces together, you'll realize Facebook's smartwatch could be used to enhance control of its VR and AR devices, or to expand its social networks into the Internet of Things (IoT) and perhaps succeed where the Portal failed. Facebook could also eventually upgrade its watches with CTRL-Labs' technologies and enable users to control other IoT devices with their minds.</p>\n<h2>But let's not get ahead of ourselves... yet</h2>\n<p>Facebook has reportedly spent about $1 billion on the development of its smartwatch over the past few years, but it only initially plans to ship volumes in the low six figures.</p>\n<p>That would make Facebook a tiny smartwatch maker compared to <b>Apple</b> (NASDAQ:AAPL), which grew its Apple Watch shipments 19% to 33.9 million in 2020, according to Counterpoint Research. Apple ended the year with a whopping 40% share of the global smartwatch market.</p>\n<p>Facebook likely realizes its smartwatch will face the same three problems that plagued the Portal: a deep distrust of Facebook's brand, privacy concerns, and its late arrival into a saturated market. Google also encountered similar criticisms after its recent takeover of Fitbit.</p>\n<p>Facebook reportedly plans to launch its smartwatch next summer for about $400. But a lot could happen within the next year, and new smartwatches -- including a new version of the Apple Watch -- could easily steal Facebook's thunder. A smartwatch with two cameras could also be considered complicated and redundant, especially when smartphones and action cameras serve the same purposes.</p>\n<h2>The key takeaways</h2>\n<p>The global smartwatch market could still grow from $59 billion this year to nearly $100 billion in 2025, according to Research and Markets. That's great news for Apple, but it also suggests the market might still be big enough for newcomers like Facebook to gain a foothold.</p>\n<p>But investors should take all these rumors with a grain of salt until Facebook actually makes an official announcement. Even if Facebook's smartwatch fares better than the Portal, it probably won't generate a meaningful percentage of its revenue or reduce its overall dependence on ads.</p>\n<p>Instead, it should be considered a potential expansion of its ecosystem beyond PCs and phones, which might just complement its ongoing push into the virtual and augmented reality markets.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Facebook's Hardware Business Is Creeping Into Apple's Backyard</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFacebook's Hardware Business Is Creeping Into Apple's Backyard\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 23:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/16/facebooks-hardware-business-is-creeping-into-apple/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Facebook (NASDAQ:FB) could be developing a smartwatch with two cameras, according to The Verge. The camera on the front will likely be used for video calls, while the rear camera can be detached to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/16/facebooks-hardware-business-is-creeping-into-apple/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09086":"华夏纳指-U","AAPL":"苹果","03086":"华夏纳指"},"source_url":"https://www.fool.com/investing/2021/06/16/facebooks-hardware-business-is-creeping-into-apple/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143978737","content_text":"Facebook (NASDAQ:FB) could be developing a smartwatch with two cameras, according to The Verge. The camera on the front will likely be used for video calls, while the rear camera can be detached to capture photos and videos for Facebook's family of apps.\nFacebook is also reportedly in talks with companies to develop accessories for attaching the camera to backpacks and other objects. Previous rumors regarding the watch suggested it will sport health-tracking features, run on a stand-alone cellular connection, and use a custom version of the Android operating system. Could this long-rumored device help Facebook challenge Apple (NASDAQ:AAPL) in the smartwatch market?\nWhy is Facebook developing a smartwatch?\nFacebook generated 97% of its revenue from ads last quarter. The remaining 3% came from its \"other\" businesses, which include its Oculus virtual reality (VR) headsets and Portal smart screens. It might initially seem odd for Facebook to add a smartwatch to that lineup, but it would actually complement its previous hardware strategies.\nFacebook's strongest hardware business is its lineup of Oculus VR headsets. It could ship at least three million Oculus Quest 2 headsets this year, according to SuperData. That would make the stand-alone VR headset, which doesn't require a PC or phone, the clear leader of its niche market.\nLooking beyond VR devices, Facebook is developing augmented reality (AR) glasses that will use similar controls as its Oculus headsets. It also acquired CTRL-Labs, which is developing a wristband that can use brain signals to control computers, in late 2019. In theory, CTRL-Labs' technology could eventually enable users to control VR and AR devices with \"mind-reading\" wristbands instead of controllers in the future.\nMeanwhile, Facebook's Portal devices haven't gained much momentum against Amazon (NASDAQ:AMZN) or Alphabet's (NASDAQ:GOOGL) (NASDAQ:GOOG) Google in the smart screen market. That failure likely dashed Facebook's hopes of expanding its social networking platforms beyond PCs and phones and into connected homes.\nWhen you put all those pieces together, you'll realize Facebook's smartwatch could be used to enhance control of its VR and AR devices, or to expand its social networks into the Internet of Things (IoT) and perhaps succeed where the Portal failed. Facebook could also eventually upgrade its watches with CTRL-Labs' technologies and enable users to control other IoT devices with their minds.\nBut let's not get ahead of ourselves... yet\nFacebook has reportedly spent about $1 billion on the development of its smartwatch over the past few years, but it only initially plans to ship volumes in the low six figures.\nThat would make Facebook a tiny smartwatch maker compared to Apple (NASDAQ:AAPL), which grew its Apple Watch shipments 19% to 33.9 million in 2020, according to Counterpoint Research. Apple ended the year with a whopping 40% share of the global smartwatch market.\nFacebook likely realizes its smartwatch will face the same three problems that plagued the Portal: a deep distrust of Facebook's brand, privacy concerns, and its late arrival into a saturated market. Google also encountered similar criticisms after its recent takeover of Fitbit.\nFacebook reportedly plans to launch its smartwatch next summer for about $400. But a lot could happen within the next year, and new smartwatches -- including a new version of the Apple Watch -- could easily steal Facebook's thunder. A smartwatch with two cameras could also be considered complicated and redundant, especially when smartphones and action cameras serve the same purposes.\nThe key takeaways\nThe global smartwatch market could still grow from $59 billion this year to nearly $100 billion in 2025, according to Research and Markets. That's great news for Apple, but it also suggests the market might still be big enough for newcomers like Facebook to gain a foothold.\nBut investors should take all these rumors with a grain of salt until Facebook actually makes an official announcement. Even if Facebook's smartwatch fares better than the Portal, it probably won't generate a meaningful percentage of its revenue or reduce its overall dependence on ads.\nInstead, it should be considered a potential expansion of its ecosystem beyond PCs and phones, which might just complement its ongoing push into the virtual and augmented reality markets.","news_type":1},"isVote":1,"tweetType":1,"viewCount":328,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}